Preclinical and early-phase clinical investigations in malignancies such as prostate, lung, and colorectal cancer demonstrate encouraging outcomes, endorsing the potential of PDE inhibitors as supplementary therapies to existing cancer treatments. The gene discussed is ALDH7A1; the disease is cancer.